India, Sept. 18 -- India's private vaccine market has been one of the steadier growth pockets within pharma, driven less by government tenders and more by rising household willingness to pay for preventive care against diseases that were once treated only after the fact. Dengue has sat outside that market for years simply because no approved vaccine existed for it in the country, leaving prevention efforts dependent on vector control and public health messaging alone. Dr. Reddy's latest tie-up with Takeda changes that equation for the first time.

Shares of Dr Reddys Laboratories Ltd. were trading at Rs. 1,196.10, up 1.80 percent from previous close of Rs. 1,175.00. The stock opened at Rs. 1,182.60, reaching an intraday high of Rs. 1,207...